Bashar Kahaleh

List of Publications by Year
in descending order

37 papers	4,463 citations	394421 19 h-index	414414 32 g-index
38 all docs	38 docs citations	38 times ranked	5519 citing authors

#	Article	IF	Citations
1	Genome-wide DNA methylation pattern in systemic sclerosis microvascular endothelial cells: Identification of epigenetically affected key genes and pathways. Journal of Scleroderma and Related Disorders, 2022, 7, 71-81.	1.7	4
2	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Expertsâ€™ Consensus. Autoimmunity Reviews, 2021, 20, 102738.	5.8	38
3	ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies. Rheumatology, 2021, 60, 5509-5516.	1.9	10
4	Epigenetic downâ€regulation of microRNAâ€126 in scleroderma endothelial cells is associated with impaired responses to VEGF and defective angiogenesis. Journal of Cellular and Molecular Medicine, 2021, 25, 7078-7088.	3.6	10
5	Similarities between COVID-19 and systemic sclerosis early vasculopathy: A â€œviralâ€•challenge for future research in scleroderma. Autoimmunity Reviews, 2021, 20, 102899.	5.8	15
6	Mechanism and biomarkers in aortitisâ€“â€“a review. Journal of Molecular Medicine, 2020, 98, 11-23.	3.9	13
7	Ultrasound-mediated topical delivery of econazole nitrate with potential for treating Raynaud's phenomenon. International Journal of Pharmaceutics, 2020, 580, 119229.	5.2	6
8	Epigenetics and systemic sclerosis: An answer to disease onset and evolution?. European Journal of Rheumatology, 2020, 7, S147-S156.	0.6	4
9	Epigenetics and systemic sclerosis: An answer to disease onset and evolution?. European Journal of Rheumatology, 2020, 7, 147-156.	0.6	11
10	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.7	13
11	Evaluation of topical econazole nitrate formulations with potential for treating Raynaudâ€™s phenomenon. Pharmaceutical Development and Technology, 2019, 24, 689-699.	2.4	8
12	Epigenetics of Systemic Sclerosis. , 2019, , 505-528.		0
13	Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. Frontiers in Immunology, 2018, 9, 2191.	4.8	53
14	Recurrent Episodes of Myocardial Infarction in a 25-Year-Old Young Man With Systemic Lupus Erythematosus. Archives of Rheumatology, 2018, 33, 102-104.	0.9	0
15	Mechanisms of Vascular Disease. , 2017, , 221-244.		1
16	Epigenetics of Systemic Sclerosis. , 2017, , 1-24.		0
17	Progress and Priorities in Systemic Sclerosis: The Next 10 Years â€“ Report from the World Scleroderma Foundation. Journal of Scleroderma and Related Disorders, 2016, 1, 7-9.	1.7	3
18	Potential beneficial role for endothelin in scleroderma vasculopathy: inhibition of endothelial apoptosis by type B endothelin-receptor signaling. Journal of Scleroderma and Related Disorders, 2016, 1, 213-219.	1.7	0

#	Article	IF	Citations
19	Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Research and Therapy, 2016, 18, 228.	3.5	30
20	Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. Rheumatology, 2016, 55, 745-754.	1.9	24
21	Recent updates in experimental protocols for endothelial cells. Journal of Scleroderma and Related Disorders, 2016, 1, 257-265.	1.7	3
22	Epigenetics and systemic sclerosis. Seminars in Immunopathology, 2015, 37, 453-462.	6.1	27
23	Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology, 2015, 54, 1759-1770.	1.9	73
24	Endothelial dysfunction in systemic sclerosis. Current Opinion in Rheumatology, 2014, 26, 615-620.	4.3	77
25	International consensus criteria for the diagnosis of Raynaud's phenomenon. Journal of Autoimmunity, 2014, 48-49, 60-65.	6.5	170
26	Cardiovascular disease in autoimmune rheumatic diseases. Autoimmunity Reviews, 2013, 12, 1004-1015.	5.8	232
27	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
28	Review: Evidence That Systemic Sclerosis Is a Vascular Disease. Arthritis and Rheumatism, 2013, 65, 1953-1962.	6.7	339
29	Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. Journal of Cellular and Molecular Medicine, 2013, 17, 1291-1299.	3.6	76
30	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
31	Vascular Disease in Scleroderma: Mechanisms of Vascular Injury. Rheumatic Disease Clinics of North America, 2008, 34, 57-71.	1.9	113
32	Association between enhanced type I collagen expression and epigenetic repression of theFLI1 gene in scleroderma fibroblasts. Arthritis and Rheumatism, 2006, 54, 2271-2279.	6.7	319
33	The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis and Rheumatism, 2005, 52, 3618-3628.	6.7	55
34	Progress in research into systemic sclerosis. Lancet, The, 2004, 364, 561-562.	13.7	20
35	The effect of dynamic versus isometric resistance training on pain and functioning among adults with osteoarthritis of the knee. Archives of Physical Medicine and Rehabilitation, 2002, 83, 1187-1195.	0.9	209
36	An elderly man with vasculitis and IgA myeloma. Journal of the European Academy of Dermatology and Venereology, 1998, 10, 186-187.	2.4	4

#	Article	IF	Citations
37	Raynaud's phenomenon and scleroderma dysregulated neuroendothelial control of vascular tone. Arthritis and Rheumatism, 1995, 38, 1-4.	6.7	95